Infiltrating CD57+ inflammatory cells in head and neck squamous cell carcinoma: Clinicopathological analysis and prognostic significance

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 3, 2012, Pages 285-290

  Fraga, Carlos Alberto De Carvalho ^a   Oliveira, Marcos Vinícius MacEdo De ^a   Domingos, Patrícia Luciana Batista ^a   Botelho, Ana Cristina De Carvalho ^a   Guimarães, André Luiz Sena ^a   Teixeira Carvalho, Andréa ^b   Correa Oliveira, Rodrigo ^b   De Paula, Alfredo Maurício Batista ^a  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

CD57 + inflammatory cells; clinicopathological factors; head and neck; prognosis; squamous cell carcinoma

Indexed keywords

CD57 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SIZE; CELL DENSITY; CELL INFILTRATION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; STROMA;

AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD57; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL MOVEMENT; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 84859908892     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318228357b     Document Type: Article

References (50)

1. De Paula AM, Souza LR, Farias LC, et al. Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. Oral Oncol. 2009;45:777-782.
2. Farias LC, Fraga CA, De Oliveira MV, et al. Effect of age on the association between p16CDKN2A methylation and DNMT3B polymorphism in head and neck carcinoma and patient survival. Int J Oncol. 2010;37:167-176.
3. Jefferies S, Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol. 2001;37:115-126. (Pubitemid 32146656)
4. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54:594-606.
5. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med. 1993;328:184-194.
6. Bouquot JE, Whitaker SB. Oral leukoplakia-rationale for diagnosis and prognosis of its clinical subtypes or "phases". Quintessence Int. 1994;25:133-140.
7. Whiteside TL, Chikamatsu K, Nagashima S, et al. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res. 1996;16:2357-2364. (Pubitemid 26325416)
8. Lanier LL, Le AM, Phillips JH, et al. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol. 1983;131:1789-1796. (Pubitemid 13006894)
9. Longworth MS, Laimins LA. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol. 2004;78:3533-3541. (Pubitemid 38568295)
10. Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of naturalkiller- cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2:850-861. (Pubitemid 37328903)
11. Focosi D, Bestagno M, Burrone O, et al. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol. 2010;87:107-116.
12. Gayoso I, Sanchez-Correa B, Campos C, et al. Immunosenescence of human natural killer cells. J Innate Immun. 2011;3:337-343.
13. Johansson MH, Hoglund P. The dynamics of natural killer cell tolerance. Semin Cancer Biol. 2006;16:393-403. (Pubitemid 44311506)
14. Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82:1-14. (Pubitemid 23188739)
15. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711-2720. (Pubitemid 36857634)
16. Yamada H, Kaibara N, Okano S, et al. Interleukin-15 selectively expands CD57+. Clin Immunol. 2007;124:328-335.
17. Serrano D, Monteiro J, Allen SL, et al. Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol. 1997;158:1482-1489. (Pubitemid 127469977)
18. Mollet L, Sadat-Sowti B, Duntze J, et al. CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol. 1998;10: 311-323. (Pubitemid 28132717)
19. Sadat-Sowti B. Parrot A, Quint L et al. Alveolar CD8+CD57+ lymphocytes in human immunodeficiency virus infection produce an inhibitor of cytotoxic functions. Am J Respir Crit Care Med. 1994;149:972-980.
20. Wang EC, Taylor-Wiedeman J, Perera P, et al. Subsets of CD8+, CD57+ cells in normal, healthy individuals: correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses. Clin Exp Immunol. 1993;94:297-305. (Pubitemid 23337830)
21. Nguyen Van BP, Duc HT. Analyses and perspectives in cancer immunotherapy. Biomed Pharmacother. 2006;60:621-628.
22. Subleski JJ, Wiltrout RH, Weiss JM. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J Autoimmun. 2009;33:275-281.
23. Arany I, dler-Storthz K, Chen Z, et al. Differentiation markers in oral carcinoma cell lines and tumors. Anticancer Res. 1997;17: 4607-4610. (Pubitemid 28081752)
24. Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol. 2006;16:383-392. (Pubitemid 44322045)
25. Das SN, Khanna NN, Khanna S. In vivo and in vitro observation of cellular immune parameters in squamous cell carcinoma of the oral cavity and its correlation with tumor load and prognosis. Cancer Invest. 1986;4:207-216. (Pubitemid 16005279)
26. Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol. 2003;21:3-7. (Pubitemid 37127467)
27. Barnes L, Eveson JW, Reichart P, et al. World Health Organization Classification of Tumours. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005.
28. Bryne M, Nielsen K, Koppang HS, et al. Reproducibility of two malignancy grading systems with reportedly prognostic value for oral cancer patients. J Oral Pathol Med. 1991;20:369-372.
29. Bryne M, Koppang HS, Lilleng R, et al. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol. 1992;166:375-381.
30. Menon AG, Janssen-van Rhijn CM, Morreau H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004;84:493-501. (Pubitemid 41656477)
31. Sakakura K, Chikamatsu K, Takahashi K, et al. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2006;55:151-159. (Pubitemid 41682587)
32. Turkseven MR, Oygur T. Evaluation of natural killer cell defense in oral squamous cell carcinoma. Oral Oncol. 2010;46:e34-e37.
33. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867. (Pubitemid 36019639)
34. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. 1987;95:229-249.
35. Bryne M, Koppang HS, Lilleng R, et al. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med. 1989;18:432-437. (Pubitemid 20057773)
36. De Oliveira MV, Fraga CA, Gomez RS, et al. Immunohistochemical expression of interleukin-4, -6, -8, and -12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinoma. Head Neck. 2009;31:1439-1446.
37. Balkwill F. Chemokine biology in cancer. Semin Immunol. 2003; 15:49-55. (Pubitemid 36092178)
38. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43: 374-379.
39. Pries R, Wollenberg B. Cytokines in head and neck cancer. Cytokine Growth Factor Rev. 2006;17:141-146. (Pubitemid 43949076)
40. Souza LR, Fonseca-Silva T, Santos CC, et al. Association of mast cell, eosinophil leucocyte and microvessel densities in actinic cheilitis and lip squamous cell carcinoma. Histopathology. 2010;57:796-805.
41. van Herpen CM, van der Laak JA, de Vries IJ, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res. 2005;11:1899-1909. (Pubitemid 40471856)
42. Eilber FR, Morton DL, Ketcham AS. Immunologic abnormalities in head and neck cancer. Am J Surg. 1974;128:534-538.
43. Lundy J, Wanebo H, Pinsky C, et al. Delayed hypersensitivity reactions in patients with squamous cell cancer of the head and neck. Am J Surg. 1974;128:530-533.
44. Mandel MA, Kiehn CL. The prognostic significance of delayed cutaneous reactivity in head and neck cancer patients. Plast Reconstr Surg. 1974;53:72-76.
45. Uppaluri R, Dunn GP, Lewis JS Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun. 2008;8:16.
46. Young MR. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck. 2006;28:462-470. (Pubitemid 43673082)
47. Schantz SP, Hsu TC, Ainslie N, et al. Young adults with head and neck cancer express increased susceptibility to mutagen-induced chromosome damage. JAMA. 1989;262:3313-3315. (Pubitemid 20012554)
48. Field JK, Pavelic ZP, Spandidos DA, et al. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1993;119:1118-1122. (Pubitemid 23303092)
49. Scully C, Bagan J. Oral squamous cell carcinoma: overview of current understanding of aetiopathogenesis and clinical implications. Oral Dis. 2009;15:388-399.
50. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88:577-583. (Pubitemid 30056932)